Related Experiment Video

Updated: Jul 3, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling

Priya Weerasinghe1, Yifei Li, Yongli Guan

  • 1Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.

The Prostate
|July 11, 2008
PubMed
Abstract

Insights

A novel STAT3-inhibiting G-quartet oligodeoxynucleotide (GQ-ODN), T40214, shows promise for prostate cancer (PC) treatment. This compound effectively inhibits STAT3 activation and promotes apoptosis in PC cells and tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Prostate cancer (PC) is a leading cause of cancer death in men, with limited treatment options for advanced stages.
  • Signal transducer and activator of transcription 3 (STAT3) is a key mediator of oncogenic signaling, active in 82% of PC patients.
  • STAT3 inhibition presents a promising therapeutic target for PC, as it regulates genes involved in apoptosis, cell cycle, and angiogenesis.

Purpose of the Study:

  • To develop and evaluate the efficacy of a novel STAT3-inhibiting G-quartet oligodeoxynucleotide (GQ-ODN), T40214, for prostate cancer treatment.
  • To investigate the mechanism of action of T40214, particularly its effects on STAT3 activation and downstream pathways.

Main Methods:

  • In vitro and in vivo assays were utilized, including Western blots, electrophoretic mobility shift assays (EMSA), cell cycle analysis, and TUNEL assays.
  • Xenograft models in nude mice were employed to assess the anti-tumor efficacy of T40214/polyethylenimine (PEI) complex in vivo.

Main Results:

  • T40214 significantly inhibited STAT3 activation and induced apoptosis in both androgen-dependent and androgen-independent PC cells.
  • The T40214/PEI complex demonstrated significant suppression of prostate tumor growth in vivo.
  • In vivo, T40214 reduced STAT3 activation, promoted apoptosis, and decreased angiogenesis and cell proliferation within prostate tumors.

Conclusions:

  • STAT3 is a critical oncogenic signal driving prostate cancer progression.
  • The T40214/PEI complex represents a promising therapeutic candidate for prostate tumors.
  • This study introduces a novel strategy for prostate cancer therapy by targeting STAT3 with GQ-ODN.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...